Acid–Base Disorder

Lactic Acidosis & the Anion Gap

Lactate is the single most common unmeasured anion in hospitalized patients. Lactic acidosis is a leading cause of high anion gap metabolic acidosis, and classifying it as Type A or Type B is the first decision point in the workup.

What is lactic acidosis?

Lactic acidosis is the accumulation of lactate and its accompanying hydrogen ion in the blood, producing a metabolic acidosis. Lactate is the anion of lactic acid, generated as the end-product of anaerobic glycolysis when pyruvate is shunted away from mitochondrial oxidation and reduced to lactate by lactate dehydrogenase. At normal concentrations (serum lactate < 2 mmol/L) it is harmless and constantly produced; at concentrations above 4–5 mmol/L it becomes a major acid load and a defining cause of high anion gap metabolic acidosis (HAGMA).

Lactic acidosis is the most frequent single cause of an elevated anion gap in the emergency department and ICU. A high anion gap in a sick patient therefore prompts an immediate serum lactate — together they are the fastest screen for tissue hypoperfusion and the most common reason to calculate the gap on admission.

Type A — tissue hypoxia

Type A lactic acidosis is caused by overt tissue hypoxia or hypoperfusion. Lactate accumulates because oxygen delivery to the mitochondria falls below the cell's metabolic demand, forcing anaerobic glycolysis. The common scenarios are:

Septic shock. The dominant cause; macro- and microcirculatory failure plus mitochondrial dysfunction ("cytopathic hypoxia"). A rising lactate is itself part of the definition of septic shock and a key resuscitation target.
Cardiogenic shock and severe heart failure. Low cardiac output delivering insufficient oxygen to the periphery.
Hypovolemic / hemorrhagic shock. Blood loss, dehydration, or third-spacing reduces preload and cardiac output.
Mesenteric or limb ischemia. Bowel infarction or arterial occlusion; lactate often climbs dramatically and may be the first clue to a surgical emergency.
Severe anemia, hypoxemia, or CO poisoning. Any state in which oxygen-carrying capacity or delivery is critically reduced.

Type A is by far the most common form of lactic acidosis encountered clinically, and the threshold for action is low: in a shocked patient the lactate trend drives fluid, vasopressor, and source-control decisions in real time.

Type B — non-hypoxic causes

Type B lactic acidosis occurs without clinical evidence of tissue hypoperfusion. Lactate accumulates from impaired mitochondrial oxidation, increased aerobic glycolysis, or reduced lactate clearance (Kraut & Madias, CJASN). The classic subgroups:

B1 — medications and toxins. Metformin (the most notorious — metformin-associated lactic acidosis, or MALA), nucleoside reverse-transcriptase inhibitors (mitochondrial toxicity), linezolid, propylene glycol (a common IV vehicle), salicylates, cyanide, and carbon monoxide in select settings.
B2 — systemic disease. Malignancy (lymphomas, leukemias, solid tumors with high glycolytic rate — the Warburg effect), hepatic failure (impaired lactate clearance), diabetic kidney disease, severe asthma (β-agonist-driven lactate), and thiamine deficiency.
B3 — inborn errors of metabolism. Mitochondrial myopathies, pyruvate dehydrogenase deficiency, glycogen storage diseases. Usually present in childhood but can manifest in adults under metabolic stress.

Many patients blur the Type A / Type B boundary — sepsis produces both hypoperfusion and mitochondrial dysfunction simultaneously, and metformin accumulation in shock becomes a hybrid problem. The classification is a clinical starting point, not a rigid partition.

D-lactate vs L-lactate

The human enzyme lactate dehydrogenase produces the L-lactate isomer exclusively. Standard laboratory lactate assays measure only L-lactate. D-lactate is the stereoisomer produced by gut bacteria in short-bowel syndrome, jejunoileal bypass, and bacterial overgrowth, and is not detected by routine lactate assays. D-lactic acidosis should be suspected in a patient with short-gut anatomy who presents with a high anion gap metabolic acidosis, a normal L-lactate, and neurological symptoms (confusion, ataxia). A specific D-lactate assay confirms it. GOLD MARK explicitly lists D-lactate as a distinct cause for this reason.

The anion gap–lactate correlation

Because lactate is an unmeasured anion, each mmol/L of lactate that accumulates widens the anion gap by approximately 1 mEq/L. In a pure lactic acidosis with no other process, the rise in anion gap should therefore roughly track the rise in serum lactate. The 1:1 relationship is the most useful bedside check:

Gap rise ≈ lactate rise — consistent with isolated lactic acidosis.
Gap rise < lactate rise — lactate is being cleared (renal or hepatic), or a coexisting process is buffering the gap (e.g. hypoalbuminemia shrinking the baseline).
Gap rise > lactate rise — a second unmeasured anion is contributing (ketones, toxins, uremia) — a mixed HAGMA.

As lactate climbs, the gap should climb with it. Use the anion gap calculator alongside the lactate on every sick-patient panel: a normal gap with a high lactate suggests early or clearing disease, hypoalbuminemia, or a lab error, while a markedly elevated gap with only a modest lactate elevation demands a search for the second acid.

Lactate > 10 mmol/L is a red flag

A serum lactate above 10 mmol/L in the absence of shock strongly suggests Type B pathology — most often metformin accumulation, malignancy, or profound mitochondrial toxicity. These are the cases where the gap-lactate gap disappears (gap rises dramatically) and bicarbonate bottoms out. They carry high mortality — metformin-associated lactic acidosis (MALA) is reported to have fatality rates of 30–50% — and frequently require renal replacement therapy for clearance (Surviving Sepsis Campaign; Kraut & Madias, CJASN).

Treatment — treat the cause

The management of lactic acidosis is the management of its underlying cause, not the number. There is no evidence that sodium bicarbonate improves outcomes in lactic acidosis — it is reserved for extreme acidaemia (arterial pH < 7.1) where haemodynamic collapse from acidosis itself is imminent, and even then only as a temporizing bridge while the cause is addressed.

Type A: restore perfusion with fluids, blood, or vasopressors; achieve source control in sepsis; revascularize ischemic territory; transfuse or oxygenate as needed.
Type B1 (metformin): stop the drug, support haemodynamics, and initiate hemodialysis early in severe MALA — metformin is dialyzable; lactate is not the only toxin to clear.
Type B2: reverse thiamine deficiency, treat the malignancy, support the failing liver.

Serial lactate and anion gap measurements guide response. A falling lactate and closing gap indicate the cause is being addressed; a plateau or rise demands re-evaluation for ongoing ischemia, uncontrolled source, or an alternative diagnosis. A detailed worked example of lactate-guided resuscitation in septic shock is in the sepsis lactic acidosis case study.